Vesalius Biocapital offers venture capital
to young European innovative life science companies

Portfolio News

Ogeda - former Euroscreen

New identity reflects Ogeda’s successful transition to GPCR drug discovery & development
Ogeda develops drugs to validated GPCR targets in the areas of women’s health, inflammation and neurodegenerative diseases.
Exit through trade sale

Drug Discovery and Development


Investing phase